ଗିଲଟେରିଟିନିବ

ଗିଲଟେରିଟିନିବ
Clinical data
Trade names	Xospata
AHFS/Drugs.com	monograph
MedlinePlus	a619003
data	US DailyMed: Gilteritinib;
Pregnancy; category	AU: D ; US: N (Not classified yet) ; ;
Routes of; administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ; ℞ (Prescription only);
Identifiers
	IUPAC name 6-Ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide;
Chemical and physical data
Formula	C29H44N8O3
Molar mass	୫୫୨.୭୨ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCc1nc(C(=O)N)c(Nc2ccc(N3CCC(CC3)N4CCN(C)CC4)c(OC)c2)nc1NC5CCOCC5;
	InChI InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34); Key:GYQYAJJFPNQOOW-UHFFFAOYSA-N;

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Gilteritinib

ଗିଲଟେରିଟିନିବ (ଇଂରାଜୀ ଭାଷାରେ Gilteritinib), ଜୋସପାଟା ଏହାର ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ତୀବ୍ର ମାୟେଲଏଡ ଲିଉକେମିଆ (AML) ରୋଗରର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୬] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହି ରୋଗ ନିମନ୍ତେ ଅନ୍ୟାନ୍ୟ ଚିକିତ୍ସା ବିଫଳ ହୋଇଥଲେ ଏବଂ ନିର୍ଦ୍ଦିଷ୍ଟ ଏଫଏଲଟି୩ (FLT3) ପରିବର୍ତ୍ତନ ବା ମ୍ୟୁଟେସନ ଥିଲେ ଏହି ଔଷଧ ବହୃତ ହୁଏ | ^[୭] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୭] ଏହାର ଉପକାର ମିଳିବା ପାଇଁ ଛଅ ମାସ ଆବଶ୍ୟକ ହୋଇପାରେ ।^[୮]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଯକୃତ ସମସ୍ୟା, ଥକ୍କାଣ, ତରଳ ଝାଡ଼ା, ଅଇ, କାଶ, ଫୁଲା, ଅଣନିଶ୍ୱାସ, ନିମ୍ନ ରକ୍ତଚାପ ଏବଂ ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।^[୬] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଭିନ୍ନତା ସିଣ୍ଡ୍ରୋମ (differentiation syndrome), ଅନିୟମିତ ହୃତ୍ ସ୍ପନ୍ଦନ, ଆନାଫାଇଲକ୍‌ସିସ ଏବଂ ପୋଷ୍ଟିରିଅର୍ ରିଭର୍ସିବଲ୍ ଏନସେଫାଲୋପାଥି ସିଣ୍ଡ୍ରୋମ (PRES) ହୋଇପାରେ ।^[୬] ^[୭] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ।^[୭] ଏହା ଏକ ଟାଇରୋସିନ୍ କାଇନେଜ ଇନହିବିଟର ଯାହା ଏଫଏଲଟି୩କୁ ଅବରୋଧ କରିଥାଏ । ^[୬]

୨୦୧୮ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ର, ୨୦୧୯ରେ ୟୁରୋପ ଏବଂ ୨୦୨୦ରେ ଅଷ୍ଟ୍ରେଲିଆରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଗିଲଟେରିନିବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୫] ^[୬] ^[୯] ଯୁକ୍ତରାଜ୍ୟରେ ୪ ସପ୍ତାହ ବ୍ୟବ‌ହାର କଲେ ପ୍ରାୟ ୧୪,୨୦୦ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହୁଏ ।^[୮] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୨୩,୭୦୦ ଡଲାର ଅଟେ ।^[୧୦]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Xospata Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 11 April 2020. Archived from the original on 10 December 2020. Retrieved 16 August 2020.
↑ "Gilteritinib (Xospata) Use During Pregnancy". Drugs.com. 20 August 2019. Archived from the original on 21 October 2020. Retrieved 16 August 2020.
↑ "Xospata EPAR". European Medicines Agency (EMA). 16 September 2019. Archived from the original on 9 December 2020. Retrieved 16 August 2020.
↑ "Xospata 40 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 13 November 2019. Archived from the original on 8 December 2020. Retrieved 16 August 2020.
↑ ^୫.୦ ^୫.୧ "Xospata- gilteritinib tablet". DailyMed. 31 May 2019. Archived from the original on 9 December 2020. Retrieved 16 August 2020.
↑ ^୬.୦ ^୬.୧ ^୬.୨ ^୬.୩ ^୬.୪ "Xospata". Archived from the original on 9 December 2020. Retrieved 3 December 2021.
↑ ^୭.୦ ^୭.୧ ^୭.୨ ^୭.୩ "Gilteritinib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 21 January 2021. Retrieved 3 December 2021.
↑ ^୮.୦ ^୮.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1027. ISBN 978-0857114105.
↑ "AusPAR: Gilteritinib (as fumarate)". Therapeutic Goods Administration (TGA). 11 September 2020. Archived from the original on 10 December 2020. Retrieved 23 September 2020.
↑ "Xospata Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 23 April 2021. Retrieved 3 December 2021.

[Xospata_APMDS-1] ୧.୦ ^୧.୧ "Xospata Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 11 April 2020. Archived from the original on 10 December 2020. Retrieved 16 August 2020.

[Drugs.com_pregnancy-2] "Gilteritinib (Xospata) Use During Pregnancy". Drugs.com. 20 August 2019. Archived from the original on 21 October 2020. Retrieved 16 August 2020.

[Xospata_EPAR-3] "Xospata EPAR". European Medicines Agency (EMA). 16 September 2019. Archived from the original on 9 December 2020. Retrieved 16 August 2020.

[4] "Xospata 40 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 13 November 2019. Archived from the original on 8 December 2020. Retrieved 16 August 2020.

[PI2021-5] ୫.୦ ^୫.୧ "Xospata- gilteritinib tablet". DailyMed. 31 May 2019. Archived from the original on 9 December 2020. Retrieved 16 August 2020.

[EPAR2021-6] ୬.୦ ^୬.୧ ^୬.୨ ^୬.୩ ^୬.୪ "Xospata". Archived from the original on 9 December 2020. Retrieved 3 December 2021.

[AHFS2021-7] ୭.୦ ^୭.୧ ^୭.୨ ^୭.୩ "Gilteritinib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 21 January 2021. Retrieved 3 December 2021.

[BNF81-8] ୮.୦ ^୮.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1027. ISBN 978-0857114105.

[TGA2021-9] "AusPAR: Gilteritinib (as fumarate)". Therapeutic Goods Administration (TGA). 11 September 2020. Archived from the original on 10 December 2020. Retrieved 23 September 2020.

[10] "Xospata Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 23 April 2021. Retrieved 3 December 2021.

[୧]

[୨]

[୪]

[୫]

[୩]

[୬]

[୭]

[୮]

[୯]

[୧୦]